The stock price of Windtree Therapeutics Inc (NASDAQ: WINT) has plunged by -7.87 when compared to previous closing price of 0.60, but the company has seen a -21.41% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-05-22 that Istaroxime has previously completed two positive Phase 2 studies in SCAI Stage B cardiogenic shock; the SEISMiC C study in SCAI Stage C cardiogenic shock is another step progressing to the istaroxime cardiogenic shock Phase 3 program
Is It Worth Investing in Windtree Therapeutics Inc (NASDAQ: WINT) Right Now?
WINT has 36-month beta value of 0.76. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for WINT is 0.75M, and currently, short sellers hold a 24.27% ratio of that float. The average trading volume of WINT on June 20, 2025 was 4.56M shares.
WINT’s Market Performance
The stock of Windtree Therapeutics Inc (WINT) has seen a -21.41% decrease in the past week, with a -30.37% drop in the past month, and a -67.46% fall in the past quarter. The volatility ratio for the week is 4.14%, and the volatility levels for the past 30 days are at 11.09% for WINT. The simple moving average for the last 20 days is -20.66% for WINT stock, with a simple moving average of -98.14% for the last 200 days.
Analysts’ Opinion of WINT
Many brokerage firms have already submitted their reports for WINT stocks, with Ladenburg Thalmann repeating the rating for WINT by listing it as a “Buy.” The predicted price for WINT in the upcoming period, according to Ladenburg Thalmann is $12.25 based on the research report published on June 26, 2020 of the previous year 2020.
WINT Trading at -39.56% from the 50-Day Moving Average
After a stumble in the market that brought WINT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.93% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at WINT starting from Fraser Craig, who purchase 5,431 shares at the price of $0.91 back on Oct 08 ’24. After this action, Fraser Craig now owns 8,638 shares of Windtree Therapeutics Inc, valued at $4,942 using the latest closing price.
Stock Fundamentals for WINT
Current profitability levels for the company are sitting at:
- -482.98 for the present operating margin
- 0.47 for the gross margin
The net margin for Windtree Therapeutics Inc stands at -461.09. The total capital return value is set at -1.07. Equity return is now at value -120.01, with -56.45 for asset returns.
Based on Windtree Therapeutics Inc (WINT), the company’s capital structure generated 0.58 points at debt to capital in total, while cash flow to debt ratio is standing at -10.53. The debt to equity ratio resting at 1.36. The interest coverage ratio of the stock is -107.59.
When we switch over and look at the enterprise to sales, we see a ratio of 50.06. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.25.
Conclusion
To put it simply, Windtree Therapeutics Inc (WINT) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
